WA-KYMETA
23.3.2022 14:02:14 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com ), the communications company making mobile global, and IP Access International (www.ipinternational.net ), a leading mobile and fixed satellite solutions provider, announced today the signing of a partnership agreement to co-develop and distribute optimized solutions using Kymeta terminals, broadband and LTE services to first responders across North America.
Today, IP Access operates the nation’s largest public safety satellite network, which includes over 1,000 agency customers encompassing 1,700 unique endpoints. This agreement to deliver optimized solutions will combine Kymeta’s resilient and cost-effective electronically-steered flat panel technology with IP Access’ experience building public safety networks for mobility and remote connectivity where it has not previously existed. It will utilize coverage and bandwidth on a jointly developed, multi layered broadband network optimized specifically for public safety customers. The Kymeta enabled solution allows communication and interoperability among devices, further extending the reach of the IP Access RedPHONE service even if there is an internet outage due to malware or denial-of-service attacks.
“Kymeta is dedicated to bringing access to always-on, reliable, and mission-critical communications while on the move to the public safety and first responder market,” said Bill Marks, EVP and Chief Development Officer of Kymeta. “Our u8 products have been deployed around the world and provide a real-world solution for the defense, government, public safety, and commercial industries by enabling connectivity that is ubiquitous and more robust than ever before. We are pleased to partner with a well-established leader like IP Access who has earned the continued trust and loyalty of first responders for over two decades through the delivery of consistent, reliable products and services.”
“IP Access looks forward to a strong partner relationship with Kymeta in our joint efforts to provide resilient communications to response teams who protect and save lives,” said Bryan Hill, CEO of IP Access International. “Our customers are indifferent to what network they are on so long as it is reliable. Our goal at IP Access is to provide them with the connectivity they need on every possible network. That means 4G, 5G, GEO, MEO and LEO. Customers have capital constraints, and it is our responsibility to deliver solutions that are future proof and that is why we are partnering with Kymeta.”
The Kymeta u8 product family for mobile broadband communications are low-maintenance and low-profile for resilient communications-on-the-move (COTM) and communications-on-the-pause (COTP). The u8 product family also offers a pathway to low Earth orbit (LEO) networks as they come online over the next several years. The new partnership will allow IP Access to provide solutions that perform on today’s satellites and are enabled to work on future LEO satellite networks.
The partnership illustrates the commitment from both companies to enable critical mobile connectivity solutions for public safety and for disaster response that are more robust than ever before. Kymeta and IP Access have committed to a significant volume of equipment and satellite bandwidth to quickly fulfill the needs of public safety and first responders and grow the product suite and coverage in support of this important market.
About Kymeta
Kymeta is the leader in unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for communications-on-the-move and making mobile global. Kymeta satellite connectivity solutions offer unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions, in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for low-power, low-cost, and high-throughput communication systems that have no moving parts. Kymeta makes connecting easy – for any vehicle, vessel, aircraft, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com
About IP Access International
IP Access is a leading provider of mobile and fixed satellite internet solutions with over 20 years experience serving the satellite industry as a domestic and global provider. IP Access provides complete satellite communications solutions inclusive of satellite network offerings, terminal hardware, and installation and support services. Incorporated in 1999, today IP Access operates the nation’s largest satellite network of public safety agencies, which includes over 1000 agency customers encompassing 1,700 unique endpoints. At the heart of the IP Access offering is the SELECT Network, providing multiple satellite options and multiple teleports, ensuring protection against regional disasters and infrastructure disruptions while also allowing for on-demand user selectable satellite service in the event of line-of-sight or look angle obstructions.
For more information, visit ipinternational.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom